These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

44 related articles for article (PubMed ID: 36123199)

  • 1. [In patients hospitalized for COVID-19, does baricitinib reduce 28-days mortality compared to standard treatment, and is it safe?].
    Lanthier L; Plourde MÉ; Cauchon M
    Rev Med Interne; 2022 Oct; 43(10):634-635. PubMed ID: 36123199
    [No Abstract]   [Full Text] [Related]  

  • 2. Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.
    Pérez-Alba E; Nuzzolo-Shihadeh L; Aguirre-García GM; Espinosa-Mora J; Lecona-Garcia JD; Flores-Pérez RO; Mendoza-Garza M; Camacho-Ortiz A
    J Microbiol Immunol Infect; 2021 Oct; 54(5):787-793. PubMed ID: 34294593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
    Hasan MJ; Rabbani R; Anam AM; Huq SMR; Polash MMI; Nessa SST; Bachar SC
    BMC Infect Dis; 2021 May; 21(1):427. PubMed ID: 33962573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.
    Moreno-Vílchez C; Bonfill-Ortí M; Bauer-Alonso A; Notario J; Figueras-Nart I
    J Am Acad Dermatol; 2024 May; 90(5):1059-1061. PubMed ID: 38246562
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.
    Titanji BK; Farley MM; Schinazi RF; Marconi VC
    Clin Infect Dis; 2021 Dec; 73(11):e3980-e3981. PubMed ID: 32797226
    [No Abstract]   [Full Text] [Related]  

  • 6. Combination therapy of high-dose intravenous anakinra and baricitinib in patients with critical COVID-19: Promising results from retrospective observational study.
    Bektaş M; Ay M; Hamdi Uyar M; İkbal Kılıç M
    Int Immunopharmacol; 2024 Mar; 129():111586. PubMed ID: 38309091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis.
    De Greef A; Ghislain PD; Baeck M
    Eur J Dermatol; 2023 Dec; 33(6):707-709. PubMed ID: 38465563
    [No Abstract]   [Full Text] [Related]  

  • 8. JAK Inhibition with Baricitinib for Severe CVID-Related Enteropathy: a Case Report.
    Abdelmoumen A; van Montfrans J; van Wijk F; Leavis H
    J Clin Immunol; 2023 Nov; 43(8):1766-1769. PubMed ID: 37612576
    [No Abstract]   [Full Text] [Related]  

  • 9. Baricitinib treatment in children with COPA syndrome.
    Matucci-Cerinic C; Corona F; Varnier GC; Pastore S; Bocca P; Palmeri S; Ravelli A; Caorsi R; Gattorno M; Tommasini A; Volpi S
    J Allergy Clin Immunol Pract; 2024 Aug; 12(8):2201-2204. PubMed ID: 38768895
    [No Abstract]   [Full Text] [Related]  

  • 10. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
    Petrone L; Petruccioli E; Alonzi T; Vanini V; Cuzzi G; Najafi Fard S; Castilletti C; Palmieri F; Gualano G; Vittozzi P; Nicastri E; Lepore L; Grifoni A; Antinori A; Vergori A; Ippolito G; Cantini F; Goletti D
    J Infect; 2021 Apr; 82(4):58-66. PubMed ID: 33639176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alopecia areata treatment with baricitinib: different relapse phenotypes.
    Dall'Oglio F; Nasca MR; Lacarrubba F; Vitale P; Micali G
    J Dermatolog Treat; 2024 Dec; 35(1):2324832. PubMed ID: 38465657
    [No Abstract]   [Full Text] [Related]  

  • 12. Complete response of extensive alopecia areata refractory to baricitinib after five months of treatment with upadacitinib.
    De la Torre-Gomar FJ; Velasco-Amador JP; Prados-Carmona Á; Ruiz-Villaverde R
    J Dermatolog Treat; 2024 Dec; 35(1):2304630. PubMed ID: 38240097
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics of Baricitinib in Cerebrospinal Fluid and Plasma in a Patient with SPENCD.
    Romano M; Geerlink A; Demirkaya E; Berard RA; Garcia-Bournissen F
    J Clin Immunol; 2024 Mar; 44(3):78. PubMed ID: 38457012
    [No Abstract]   [Full Text] [Related]  

  • 14. Treatment of Livedoid Vasculopathy With Baricitinib.
    Song X; Tu P
    JAMA Dermatol; 2022 May; 158(5):587-589. PubMed ID: 35353137
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful Therapy of Severe and Refractory Cutaneous Sarcoidosis with Baricitinib.
    Russo G; Laffitte E
    Acta Derm Venereol; 2024 Apr; 104():adv39970. PubMed ID: 38566407
    [No Abstract]   [Full Text] [Related]  

  • 16. Refractory livedoid vasculopathy successfully treated with baricitinib.
    Xiao Y; Wang Y; Gu Y; Xia D; Li W
    Int J Dermatol; 2023 Sep; 62(9):1204-1205. PubMed ID: 36349427
    [No Abstract]   [Full Text] [Related]  

  • 17. Baricitinib rapidly improves mechanic's hands and hiker's feet in anti-synthetase syndrome.
    Hu H; Wang S
    Rheumatology (Oxford); 2024 Feb; 63(2):e65-e66. PubMed ID: 37458479
    [No Abstract]   [Full Text] [Related]  

  • 18. Chronic actinic dermatitis with excellent response to oral baricitinib.
    Agud-Dios M; Arroyo-Andrés J; Rubio-Muñiz C; Tous-Romero F
    J Dtsch Dermatol Ges; 2023 Sep; 21(9):1033-1034. PubMed ID: 37424181
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination of baricitinib and conventional immunomodulating therapy for alopecia totalis.
    Koh YG; Han HS; Seok J; Choi SY; Li K; Kim BJ; Yoo KH
    Skin Res Technol; 2023 Aug; 29(8):e13425. PubMed ID: 37632179
    [No Abstract]   [Full Text] [Related]  

  • 20. Baricitinib for systemic lupus erythematosus: not enough, or not enough evidence?
    Patoulias D; Dimosiari A; Dimitroulas T
    Clin Exp Rheumatol; 2023 Nov; 41(11):2339-2340. PubMed ID: 37279150
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.